Vantage Consulting Group Inc Moderna, Inc. Transaction History

Vantage Consulting Group Inc

$68.1 Million
Q1 2024

A detailed history of Vantage Consulting Group Inc transactions in Moderna, Inc. stock. As of the latest transaction made, Vantage Consulting Group Inc holds 2,305 shares of MRNA stock, worth $272,727. This represents 0.36% of its overall portfolio holdings.

Number of Shares

2,305

Previous 2,912 20.84%

Holding current value

$272,727

Previous $289,000 15.22%

% of portfolio

0.36%

Previous 0.45%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$85.37 - $115.44 $51,819 - $70,072	-607 Reduced 20.84%	2,305 $245,000
Q4 2023 Feb 14, 2024	BUY	$69.51 - $104.43 $52,619 - $79,053	757 Added 35.13%	2,912 $289,000
Q3 2023 Nov 14, 2023	BUY	$96.41 - $126.61 $27,669 - $36,337	287 Added 15.36%	2,155 $222,000
Q2 2023 Aug 11, 2023	BUY	$118.5 - $160.53 $15,997 - $21,671	135 Added 7.79%	1,868 $226,000
Q1 2023 May 10, 2023	BUY	$135.66 - $197.02 $51,822 - $75,261	382 Added 28.28%	1,733 $266,000

Q4 2022 Feb 13, 2023	SELL	$118.38 - $210.04 $54,454 - $96,618	-460 Reduced 25.4%	1,351 $242,000
Q3 2022 Nov 14, 2022	SELL	$118.07 - $194.18 $9,209 - $15,146	-78 Reduced 4.13%	1,811 $214,000
Q2 2022 Aug 09, 2022	BUY	$117.13 - $176.59 $26,588 - $40,085	227 Added 13.66%	1,889 $270,000
Q1 2022 May 16, 2022	BUY	$126.46 - $235.05 $81,946 - $152,312	648 Added 63.91%	1,662 $286,000
Q4 2021 Feb 14, 2022	BUY	$225.82 - $368.51 $105,006 - $171,357	465 Added 84.7%	1,014 $258,000
Q3 2021 Nov 10, 2021	BUY	$221.9 - $484.47 $121,823 - $265,974	549 New	549 $211,000
Q1 2021 May 14, 2021	SELL	$109.18 - $185.98 $655 - $1,115	-6 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$65.74 - $169.86 $394 - $1,019	6 New	6 $1,000

Others Institutions Holding MRNA

# of Institutions

1,039

Shares Held

245M

Call Options Held

12.1M

Put Options Held

9.36M

View Full List

About Moderna, Inc.

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $46.3B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

More about MRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vantage Consulting Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vantage Consulting Group Inc with notifications on news.

Account

Vantage Consulting Group Inc Moderna, Inc. Transaction History